Lv3
350 积分 2021-12-16 加入
Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in active rheumatoid arthritis refractory to biologic disease-modifying antirheumatic drugs
18天前
已完结
Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double‐Blind, Randomized Controlled Trial
18天前
已完结
Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial
18天前
已完结
New frontiers in rheumatoid arthritis therapy: From classic DMARDs to biologics and beyond
18天前
已完结
Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study
18天前
已完结
Adalimumab
20天前
已完结
DB-2304, a Duality Immune Modulating Antibody‒Drug Conjugate (DIMAC) targeting BDCA2, displays strong potency in the suppression of pDC functions
23天前
已完结
Pushing the Envelope: Advancement of ADCs Outside of Oncology
23天前
已完结
TNF and TNF receptors as therapeutic targets for rheumatic diseases and beyond
24天前
已完结
Unravelling the potential of small molecule tumor necrosis factor-α (TNF) inhibitors: A comprehensive review
24天前
已完结
皖公网安备34019202002308
